It’s like drifting back to the nineties and being caught in the crossfire of the war of words with the likes of Oracle and Salesforce all over again. I’m feeling quite nostalgic - and actually rather ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated ...

These response and remission rates - ranging from 70%-90% of patients - are much higher than we would expect from standard-of-care for this cancer type, which typically leads to remission in only ...